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Abstract 
 
A PIPELINE FOR TAGGING snRNP ASSOCIATED PROTEINS IN HeLa 
 
by 
 
John Kim 
 
The spliceosome is a dynamic eukaryotic macromolecular complex responsible 
for catalysis of pre-mRNA splicing. High quality processing of a pre-mRNA by 
removal of non-coding introns and ligation of exons is essential to preserve the 
accuracy of a mature RNA transcript that will undergo eventual translation into a 
functional protein. Given the irresolute nature of the spliceosome, much of the 
machinery underlying the structural rearrangements that occur throughout the 
splice cycle have yet to be fully characterized. Thus far, biochemical 
characteristics of spliceosome assembly in humans have been studied by 
complexes purified by in-vitro reconstitution with HeLa nuclear extract and a 
transcribed radiolabeled pre-mRNA substrate. While in-vitro reconstitution has 
been a standard for purification of both human and yeast spliceosomes, studies in 
yeast have also been able to utilize endogenous protein tags to study the physical 
nature of spliceosome intra-interactions. Here we have re-purposed a RMCE 
protocol from Khandelia et al. to endogenously express V5-tagged snRPB2, a 
core component of the U2 snRNP, in HeLa cells. Our tagged construct was 
integrated into the HeLa cell genome by Cre-Lox recombination and construct 
expression is regulated by a TET-ON system. Selected HeLa cells were then 
induced to express V5-tagged snRPB2 for eventual purification of the tagged 
 viii
protein and its endogenous interactions by co-immunoprecipitation (Co-IP). Mass 
spectrometry data revealed the Co-IP eluent contains all the components of an 
endogenously assembled U2snRNP from active HeLa nuclear extract. Altogether, 
these preliminary results open the door for a pipeline to study biochemical 
characteristics of mammalian spliceosomal complexes purified via endogenously 
tagged proteins.  
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Chapter 1 
Introduction 
1.1 Eukaryotic Pre-mRNA Splicing  
Nascent pre-mRNA transcripts in eukaryotes consist of both protein coding 
(exons) and non-coding (introns) sequence. The removal of intronic stretches of 
sequence interspersed within the transcript and subsequent ligation of exons is a 
process known as pre-mRNA splicing. The resulting mature mRNA goes on to be 
translated into a functional polypeptide by the ribosome. Splicing at the proper 
exon-intron junctions of a pre-mRNA substrate is key in order to maintain the 
correct sequence for translation. Defects in splicing and its corresponding 
machinery have the potential to alter the amino acid sequence of a polypeptide 
thus altering a protein’s structure and function in the cell.  
The spliceosome is a macromolecular RNA-protein complex responsible for 
catalysis of splicing on pre-mRNA substrates. Spliceosomes consist of uridine 
rich small nuclear ribonucleoprotein particles (snRNPs) and non-snRNP auxiliary 
factors that assemble de novo on pre-mRNA substrates (Staley and Woolford Jr. 
2009). The cycle in which de novo assembly and subsequent 
rearrangement/removal of core and auxiliary factors, that result in the various 
complexes of the spliceosome, is known as the splice cycle. 
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1.2 Splicing Chemistry and Intronic Elements 
Introns are excised from pre-mRNA via the splice cycle in two 
transesterification steps: branching and exon ligation. Branching occurs when the 
phosphorus of the 5’ exon-intron junction (5’ splice site) undergoes a nucleophilic 
attack by the 2’-hydroxyl group of an adenosine within the intron (branch point 
adenosine). The result produces a free upstream exon and a branched intron (lariat 
intron) that remains bound to the 3’ exon. During second step chemistry, the last 
nucleotide of the free 5’ exon performs a nucleophilic attack at the 3’ splice site, 
effectively releasing the lariat intron and ligating the exons together (Figure 
1.1A). 
 
Figure 1.1: Schematic diagram of splicing chemistry and representation of 
conserved intron sequences in yeast and humans. (A) Introns are removed via 
two transesterification reactions in succession. The 5’ splice site, 3’ splice site and 
branch point adenosine are denoted as 5’SS, 3’SS and BrA, respectively. Red 
arrows denote nucleophilic attacks. (B) Intron motifs implicated in recognition by 
the spliceosome are highly conserved in yeast compared to that of humans. Y 
denotes any pyrimidine, N denotes any nucleotide, R denotes any purine. Adapted 
from Nagai et al. 2018. 
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Within introns lie conserved sequences that function to help define intron 
boundaries for the spliceosome: the 5’ splice site, the 3’ splice site, the branch 
point sequence, and the polypyrimidine tract. Both 5’ and 3’ splice sites, GU and 
AG respectively, are invariant dinucleotides that delineate the start and end of the 
intron. Although these dinucleotides are highly conserved across species, the 
consensus sequences surrounding them can vary across and even within a species 
(Figure 1.1B).  
The branch point sequence (BPS) is a stretch of seven nucleotides, upstream 
of the 3’ splice site, that houses the branch point adenosine. In yeast, the BPS is 
highly conserved, UACUAAC (Newman et al. 1985) while in humans the 
sequence is mostly degenerate; YNYURAY (Ruskin et al. 1985) (Figure 1.1B). 
 In higher eukaryotes, the polypyrimidine tract (PYT) is a stretch of 15-20 
pyrimidines adjacent to the 3’ splice site. The PYT that has been shown to recruit 
splicing factors, such as U2AF, required for binding of the U2snRNP (Ruskin et 
al. 1988) (Figure 1.1B). 
1.3 The Splice Cycle  
The splice cycle is divided into multiple stages: assembly, catalysis, and 
disassembly. In summary, initiation of assembly begins when the 5’ splice site is 
recognized and bound by the U1 snRNP along with binding of non-snRNP factors 
SF1 and U2AF to the BPS and PPT, respectively (Liu et al. 2001; Ruskin et al. 
1988). 
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The commitment complex, E complex, (Reed et al. 1990) transitions to A 
complex when the U2 snRNP binds the BPS via base pair interactions with the U2 
snRNA (Query et al. 1994). Prior to catalysis, a pre-assembled U4/U6.U5 tri-
snRNP associates with A complex to form pre-B complex, a fully assembled 
spliceosome (Stevens and Abelson 1999; Boseler et al. 2016). Transfer of the 5’ 
splice site from U1 to U6 snRNA via Prp28, followed by unwinding of the U4/U6 
snRNA duplex by Brr2, results in dissociation of U1, U4/U6 proteins, and the U4 
snRNA (Staley and Guthrie 1999; Raghunathan and Guthrie 1998; Laggerbauer et 
al. 1998). This allows for the formation of the catalytic core of the spliceosome by 
base pair interactions of U2 and U6 snRNA resulting in Bact complex which in 
turn is converted to B* by a DEAH-box helicase, Prp2 (Madhani and Guthrie 
1992; Warkocki et al. 2009). This B* complex catalyzes the first 
transesterification step of splicing (nucleophilic attack of the 5’ splice site by the 
BrA) followed by C and C*complexes which catalyze the second step 
(nucleophilic attack of the 3’exon by the 5’ exon). Finally, exon ligation generates 
the mRNA, in P complex, which is released by the helicase Prp22 and snRNPs are 
recycled for subsequent rounds of splicing (Company, Arenas and Abelson 1991; 
Schwer 2008).  
1.4 Current Spliceosome Structures and Purification Methods 
Three-dimensional modeling of the spliceosome via X-ray crystallography 
and cryo-electron microscopy have provided much insight behind the potential 
mechanics that govern the various conformations of the spliceosome. Advances in 
 5
cryo-EM technology have led to high resolution cryo-EM structures of the 
spliceosome. In 2015, the intron lariat spliceosome (ILS) complex in S. pombe 
was solved at a resolution of 3.6 Å (Yan et al. 2015). Furthermore, over the past 
three years (2015-2018), the Shi, Nagai, and Luhrmann labs have provided 17 
additional cryo-EM structures of both yeast and human spliceosomes ranging 
from 3.3 to 9.9 Å resolutions. 
 Of the 17 structures, the human structures include that of B, Bact, C, C*, and 
the U4/U6.U5 tri-snRNP (reviewed by Shi 2019). Human spliceosomes thus far 
have been purified by in-vitro assembly on a synthetic pre-mRNA substrate with 
an MS2-tag (Jurica et al 2002; Zhou et al. 2002) compared to direct purification 
by affinity tags of endogenously assembled yeast structures (Ohi et al. 2007; Yan 
et al. 2015). Compared to yeast, human spliceosomes share many attributes such 
as active site conformation, structural organization, and intra-interactions of RNA 
and proteins. However, additional proteins are present in human structures that 
are not found in yeast (reviewed by Shi 2019). Furthermore, degenerate sequence 
motifs along with multiple introns per transcript present themselves as challenges 
to direct purification stable human spliceosome structures. 
1.5 Spliceosome Assembly and Substrate Recognition 
Higher eukaryotic transcripts possess multiple introns (Michael and Manyuan 
1999) compared to a single intron per transcript ratio widely found in yeast; 
therefore, higher eukaryotic cells have a selection of branch and splice sites to 
choose from. However, the structural mechanics that define a branch point 
 6
selection by the U2 snRNP is not well understood. Commitments to the splicing 
pathway and to specific splice sites have been shown to be separate steps in the 
assembly pathway implying U1 and U2 snRNP binding are not the final factors 
behind splice site choice (Lim and Hertel 2004).  
U2 snRNP is comprised of core components such as the U2 snRNA, proteins 
SNRPA and SNRPB2, along with SF3b and SF3a splicing factors that assemble 
on to the aforementioned core components (Will et al. 2002) (Figure 1.2). Proper 
recognition of the BPS by U2 has been shown to be crucial for maintenance of 
splicing fidelity thus avoiding deleterious consequences of mis-splicing. SF3B1, a 
subunit of the SF3b splicing factor found in 17S U2 snRNPs, has been shown to 
be implicated in myelodysplastic syndromes when mutated; resulting in aberrant 
splicing through usage of alternate branch point sequences and 3’ splice sites 
(Darman et al. 2015). Wild-type SF3B1 interacts with U2AF2 at the N-terminus 
while the C-terminus of SF3B1 interacts with SF3B6, another U2 snRNP protein; 
together SF3B1 and SF3B6 have been shown to contact nucleotides flanking the 
BPS potentially stabilizing the U2/BS interaction (Gozani et al. 1998). Despite 
crystal structure data of recombinant human SF3b complexes (Cretu et al. 2016), 
the structural mechanism for SF3b subunit roles in BPS recognition and the 
purpose of the SF3b complex as a whole is unclear. Thus, a need to clarify the 
structural basis underlying the U2 snRNP’s decision making.  
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Figure 1.2: U2 snRNP components interact with the branch point sequence.  
Interaction of SF3B1 and the BPS implicates a role in branch point selection. The 
U2 snRNP is comprised of the U2 snRNA and 20 known proteins. Adapted from 
Wan and Wu 2013. 
 
1.6 Recombination Mediated Cassette Exchange 
Site specific recombination has been a key tool for molecular biologists to 
modify the genetic code of an organism by recombination of DNA. Recombinases 
such as Cre, rearrange two pieces of DNA by recognition and cleavage of specific 
sites that flank the segments of interest. Recombination mediated cassette 
exchange (RMCE) involves targeted integration of genes or whole gene cassettes, 
at a pre-defined locus containing recombination sites, that will allow for 
endogenous expression of a transgene. Donor gene cassettes, flanked by 
corresponding recombination sites, may hold a variety of genetic elements that 
contain not only a gene of interest, but also and not limited to: genes that confer 
antibiotic resistance for selection, over-expression or gene knockdown/silencing 
constructs, and inducible systems that regulate transgene expression. 
Considering that recombination results in assimilation of the donor DNA into 
the genome, it follows that integrated genes face challenges of stable expression 
and susceptibility to cis-elements in its chromosomal surroundings. To 
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circumvent this issue, RMCE protocols have established acceptor locus screens 
for favorable loci. FLP293 is a HEK293 cell line developed to produce 
retroviruses via Flippase RMCE in which clones with high and stable virus 
production were screened for and selected (Schucht et al. 2006).  
Khandelia et al. 2011 developed a similar protocol which entailed high-
efficiency and low-background RMCE (HILO-RMCE) by Cre recombination, 
resulting in inducible shRNA expression in various human and mouse cell lines. 
The authors established multiple acceptor cell lines by lentiviral transduction of a 
cassette containing a strong EF-1α promoter and a blastocidin resistance gene 
flanked by mutually incompatible Cre-specific recombination sites, Lox 2272 and 
LoxP. These cell lines were then co-transfected with a Cre-encoding plasmid and 
a donor plasmid/cassette, pRD-RIPE, containing a variety of genetic elements for 
puromycin selection, an inducible shRNA expression system, and an EGFP 
expression marker, “floxed” by Lox 2272 and LoxP sites (Figure 1.3). 
Transfected acceptor cell lines were then screened for stable integration and 
optimal expression of the trans-gene construct by FACS and RT-qPCR 
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(Khandelia et al. 2011).  
  
Figure 1.3: RMCE donor plasmid acceptor locus construct in HeLa.  
In the presence of Cre recombinase, the transfected donor plasmid exchanges 
gene cassettes at the acceptor locus flanked by corresponding Lox 2272 and LoxP 
sites. Cassette exchange results in removal of the blastocidin resistance gene 
followed by integration of puromycin resistance and an EGFP trans-gene 
regulated by a tetracycline induction module. Adapted from Khandelia et al. 2011 
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Chapter 2 
 
Materials and Methods 
 
2.1 Site Directed Mutagenesis PCR of Donor Plasmid  
To generate a pRD-RIPE donor plasmid with a 3’ NgoMIV site, pRD-
RIPE (Khandelia et al. 2011) was mutated following the NEB “Q5 site directed 
mutagenesis” PCR protocol with the following primers NgoMIV Forward and 
NgoMIV Reverse. Primer sequences are as indicated in Table 2.1. 
 PCR products were then purified using the Macherey-Nagel Gel and PCR 
purification kit. 2 µl of purified PCR products were then used for a KLD reaction 
in 10X DNA Ligase Buffer, T4 DNA Ligase, T4 PNK and Dpn1 incubated at 
16˚C overnight. 10 µl of KLD reaction was then added to 100 µl of DH5-α 
competent cells and incubated on ice for 30 minutes. KLD competent cells were 
heat shocked for 45 seconds in a 42˚C water bath and 900 µl of SOC media was 
added to the cells immediately. Cells were incubated at 37˚C shaking for 1 hour 
and 100 µl were plated onto LB ampicillin media plates. Plates were incubated at 
37˚C for 16 hours and colonies were counted, picked, and incubated into 
overnight bacterial cultures containing LB ampicillin media for 16 hours. Plasmid 
DNA was isolated from overnight bacterial cultures with the Thermo Scientific 
DNA plasmid mini prep kit. 5 µg of plasmid DNA were digested with AgeI and 
NgoMIV for 2 hours at 37˚C and ran out on a 1% agarose gel. The band with the 
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correct size was excised and gel purified using thing the Macherey-Nagel Gel and 
PCR purification kit. Purified and digested pRD-RIPE was used for the following 
ligations.  
PCR parameters: 98˚C for 30s, 30 cycles of 98˚C for 10s, 68˚C for 20s, and 
72˚C for 4 minutes, and a final extension of 72˚C for 3 minutes.  
2.2 Two-step PCR amplification, Restriction Digest, and 
purification of V5-tagged SNRPB2 gene insert  
 
V5-tagged SNRPB2 insert was generated following the NEB Phusion 
PCR protocol using a snRPB2 plasmid template and the following primers for 
PCR 1: SNRPB2 V5 Forward and SNRPB2 all Reverse. 1 µl of PCR 1 product 
was then used as template for PCR 2 following the NEB Phusion PCR protocol 
using the following primers: V5 Forward and ALL Ngo Reverse. Primer 
sequences are as indicated in Table 2.1. 
PCR 2 products were PCR purified via Macherey-Nagel Gel and PCR 
purification kit (Ref. #740609). 20 µl of purified PCR products were then 
digested in 10X CutSmart Buffer with AgeI-HF (NEB) and NgoMIV (NEB) at 
37˚C overnight. Digests were run on a 1% agarose gel and bands of the correct 
size were excised and purified using the Macherey-Nagel Gel and PCR 
purification kit (Ref. #740609). Digested and purified SNRPB2 products were 
used for following ligations. 
PCR 1 parameters: 98˚C for 30s, 35 cycles of 98˚C for 20s, 63˚C for 20s, and 
72˚C for 1 minute and 30s, and a final extension of 72˚C for 7 minutes 
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PCR 2 parameters: 98˚C for 30s, 35 cycles of 98˚C for 20s, 65˚C for 20s, and 
72˚C for 1 minute and 30s, and a final extension of 72˚C for 7 minutes 
 Table 2.1: Primer sequences for mutagenesis and two-step PCR. 
 
2.3 Ligations and Transformation 
Ligations were carried out at a 5:1 insert to vector molar ratio. 150 ng of 
digested pRD-RIPE and 93 ng of digested V5 SNRPB2 insert in a ligation 
reaction containing 10mM ATP, Ligase, 10X Ligase Buffer, and mQH20. 
Ligations were incubated at room temperature for 1 hour and the total volume 
added to DH5-alpha competent cells. Competent cells with the ligations were 
incubated on ice for 25 minutes and heat shocked in a 42˚C water bath for 
precisely 45 seconds. 900 µl of SOC media was added immediately after and 
samples were incubated in 37˚C shaking for 1 hour. Competent cells were then 
plated onto LB media plates containing Ampicillin and left overnight in the 37˚C 
Name  Sequence 
NgoMIV 
Forward 5’ ATCAGAAGGTGCCGGCTGGTGTGGCC 3’  
NgoMIV 
Reverse 5’ AGGCAGCCTGCACCTGAG 3’  
SNRPB2 
V5 
Forward 5’ CCTCGGTCTCGATTCTACGGGATCCATGGATATCAGACCAAATCATAC 3’  
SNRPB2 
all Reverse 5’ CAGCCTGCACCTGAGTGTCTATTTCTTGGCATAGGTGATC 3’  
V5 
Forward 5’ CGCACCGGTCGCCACCATGGAAGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACGG 3’  
ALL Ngo 
Reverse 5’ CGCGCCGGCACCTTCTGATAGGCAGCCTGCACCTGAGTG 3’ 
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incubator. The plates were removed the following morning and colonies picked 
and incubated in overnight cultures containing LB media and Ampicillin. Plasmid 
DNA was purified the following morning using the Thermo Scientific DNA 
plasmid mini prep kit and plasmids with pRD-ORF primers were sent for 
sequencing to UC Berkeley Sequencing to validate ligation of the insert into 
vector. 
2.4 Cell Culture 
Adherent HeLa cells containing an established acceptor locus site flanked 
or “floxed” by Lox2272 and LoxP sites were provided by (Khandelia). HeLa cells 
were cultured in high glucose DMEM medium supplemented with 10% FBS and 
passaged using 1X trypsin (HyClone). After transfection, HeLa cells were 
subjected to puromycin selection at concentrations ranging from 0.75 µg/mL-1.5 
µg/mL. Tet-inducible expression was turned on by addition of Doxycycline to a 
final concentration of 2 µg/mL. All cells were stored in 90% DMEM and 10% 
DMSO and placed in -80°C until frozen and eventually placed in liquid nitrogen 
for long term storage. 
2.5 Stable Cell Line Construction 
Stable cell lines expressing V5-tagged proteins was established in 
adherent HeLa cells via co-transfection of a donor plasmid pRD-RIPE mixed with 
a Cre-encoding plasmid, pCAGGS-Cre, (Khandelia) with the latter comprising 
1% of the total plasmid concentration. A single well from a 12-well plate was 
 14
transfected with according to the Polyplus jetPRIME® in vitro DNA transfection 
protocol. Transfected cells were left overnight and the media changed the 
following day and incubated for 24 hours. Cells were detached with trypsin, 
expanded into 6-well plates the following day, and allowed to re-adhere for an 
additional 24 hours. Adherent cells were subjected to puromycin selection the 
following day at a half maximal concentration of 0.75 µg/mL and incubated for 
24-48 hours with new puromycin media every 24 hours. Following selection, 
puromycin resistant cells were maintained at a maximal concentration of 1.5 
µg/mL. 
2.6 Genomic DNA Extraction and PCR 
Genomic DNA was extracted from ~1.3 x 107 transfected adherent HeLa 
using the “Zymogen ZR Genomic DNA Tissue Mini-Prep” kit. Genomic preps 
were quantified using a nanodrop spectrophotometer. ~100ng of genomic DNA 
was used as template for PCR with Taq polymerase using pRD-ORF primers: 
pRD-RIPE Forward and pRD-RIPE Reverse. Primer sequences are as indicated in 
Table 2.2. PCR products were run on a 1% agarose gel (1:17,000 EtBr). 
2.7 RNA Extraction and RT-PCR  
RNA was extracted using the “Qiagen RNeasy Mini” kit (syringe lysis) 
and quantified with a nanodrop spectrophotometer. 5 µg of total RNA was 
DNaseI treated following the NEB DNaseI protocol with the following 
deviations. 20 µl reactions and 0.5 µl of 0.5M EDTA instead of 100 µl reactions 
and 1 µl of 0.5M EDTA. 1 µg of DNaseI treated RNA was used as template for 
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RT-PCR in a reaction with 0.5ug of pRD-ORF Reverse primer (Table 2.2), 
10mM dNTPs, 0.5 µl of RNasin, 1 µl of M-MLV Reverse Transcriptase, 5X M-
MLV RT Buffer, and mQH2O for a total of 20 µl. RT reactions were incubated in 
a 42˚C water bath for 1 hour and heat inactivated at 95˚C for 5 mins. 1 µl of RT 
reaction was used as template for a Taq Polymerase PCR following the “NEB Taq 
Polymerase” protocol with pRD-ORF Forward and pRD-ORF Reverse primers. 
Primer sequences are as indicated in Table 2.2. 
Table 2.2: Primer sequences for Sequencing, Genomic PCR, and RT-PCR. 
Name  Sequence 
pRD-RIPE Forward 5’ AAGTTGGTCGTGAGGCACTG 3’  
pRD-RIPE Reverse 5’ CAGAAGTCAGATGCTCAAGGG 3’  
 
2.8 Whole Cell Extraction 
Approximately 1.3 x 107 adherent HeLa cells induced with doxycycline 
were pelleted and washed with Phosphate Buffer Saline (PBS). Cells were 
resuspended in RIPA Lysis Buffer containing EDTA and homogenized with a 
25G needle. The insoluble material was then pelleted at 14,000 x g and the 
supernatant collected and centrifuged once more to remove nucleic acid and 
debris for 15 minutes at 4˚C. The supernatant was then collected as whole cell 
lysate. 
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2.9 Mini Nuclear Extraction 
Approximately 1.3 x 107 adherent HeLa cells induced with doxycycline 
were pelleted and washed with ice cold PBS. The packed cell volume (PCV) was 
noted and the cells were resuspended in 1 volume of Buffer A (10mM Hepes pH 
7.9, 1.5mM MgCl2, 10mM KCl, 1mM DTT) and allow to swell on ice for 15 
minutes. A 25G hypodermic needle was used to lyse/homogenize the cell 
suspension and the cell homogenate was centrifuged for 20 seconds in a 
microcentrifuge at 14,000 g at 4˚C. The supernatant was discarded and the nuclear 
pellet was resuspended in 2/3 PCV of buffer C (20mM Hepes pH 7.9, 1.5mM 
MgCl2, 0.2mM EDTA, 25% glycerol, 0.42M KCl, 0.5mM PMSF, and 1mM 
DTT) to be incubated on ice stirring for 30 minutes. Resuspended solution was 
centrifuged at 14,000 x g to pellet the nuclear debris and the supernatant 
collected. Supernatant was dialyzed against buffer D (20mM Hepes pH 7.9, 0.1M 
KCl, 0.2mM EDTA, 20% glycerol, 1mM DTT, and 0.5mM PMSF) for 3 hours at 
4˚C and collected as nuclear extract. 
2.10 Western Blot 
Samples were loaded onto a 10% polyacrylamide gel and ran in SDS-PAGE 
buffer at 75V for 90 minutes. Gels were transferred onto nitrocellulose 
membranes in Towbin transfer buffer with SDS at 125 mA for 90 mins. 
Membranes were blocked in 1X TBST containing 1% nonfat dry milk for 1 hour 
at room temperature and primary antibody added straight to blocking buffer for 
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overnight incubation at 4° C rotating. The following day, blots were washed with 
1X TBST three times for 5 minutes each and placed in milk. Secondary antibody 
Licor IRDye 680RD Goat anti-Rabbit (#926-68071) was added directly to milk at 
a ratio of 1:15,000 and incubated for 1 hour shaking at room temperature. Blots 
were washed with 1X TBST three times for 5 minutes each following secondary 
incubation and imaged using the Licor software image scanner.  
2.11 Co-Immunoprecipitation 
Protein A magnetic beads were washed with PBS three times and 
equilibrated with 5X bead volume of extraction buffer (RIPA for whole cell 
extracts and Buffer E for nuclear extracts) in 4˚C overnight. 5 µg of V5 mouse 
monoclonal antibody (Thermo cat. #R960-25; same volume of PBS added for 
mock treatments) was added to extracts and left in 4˚C rotating for precisely 13 
hours. The following morning, beads were immobilized on a magnetic rack and 
the buffer taken off and discarded. Incubated extract was added to equilibrated 
beads and left rotating end over end in 4˚C for 4 hours. Beads were immobilized 
and the flow-through taken off and saved. Beads were resuspended/washed with 
IP Wash Buffer (10mM Tris, pH 7.5, 1mM EGTA, 150mM KCl, and 1% NP-40) 
3 times with each wash taken off immobilized beads and saved. V5 co-IP was 
eluted by resuspension/elution with 10 µl of 0.1M Glycine pH 2.5 twice for a total 
of 20 µl and quenched with 20 µl of 1M Tris pH 7.8. Finally, beads were 
incubated at 95˚C for 3 minutes in 5X SDS buffer for a “hard” elution.  
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2.12 In-vitro Splicing Reactions  
32P-radiolabeled pre-mRNA substrate (MJ50) created from T7-run off 
transcription was used for in-vitro splicing reactions carried out with the 
following components and final concentrations. 10nM MJ50, 40mM Potassium 
Glutamate, 4mM Magnesium Acetate, 2.3mM ATP, 3mM Creatine Phosphate, 
0.05 mg/ml tRNA, and 50% v/v HeLa nuclear extract were incubated at 30˚C. 
2.13 Native Gel Analysis 
Splicing reactions described as above were loaded on a 1.9% agarose gel 
made with low melting point agarose and 20mM Tris-Glycine. Native gels ran at 
72 V for 3 hours and 30 minutes, subsequently dried onto Whatman paper at 65˚C 
for 1 hour, and exposed to phosphor screens. Screens were scanned and imaged 
on a Typhoon (Molecular Dynamics) scanner. 
2.14 Denaturing Gel Analysis 
 RNA was gel-extracted from a 5% w/v denaturing polyacrylamide gel and 
in-vitro spliced. Splicing reactions were run on a 15% w/v denaturing 
polyacrylamide gel. Radiolabeled RNA was visualized by exposure to phosphor 
imaging screens. Screens were scanned and imaged on a Typhoon (Molecular 
Dynamics) scanner. 
2.15 Mass Spectrometry Prep 
Co-IP’d nuclear extract was run on a 10% polyacrylamide gel (cast with 
plates previously washed in phosphoric acid) for 30 minutes at 100V to run the 
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sample about an inch into the resolving gel. The gel was then washed briefly in 
mQH2O to remove residual SDS buffer and incubated in Coomassie G (40 g 
ammonium sulfate, 8 ml phosphoric acid 85% w/v, 0.4 g Coomassie brilliant blue 
G, mQH2O up to 400 mL and 100 mL methanol) shaking at room temperature 
overnight. The following day, the gel was washed in mQH2O to remove residual 
Coomassie G. The gel slice containing the sample was then excised and place in a 
clean Eppendorf tube to be sent to the Mass Spectrometry Facility at UCSF (For 
mass spectrometry protocol please see UCSF In-Gel Digestion Protocol). 
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Chapter 3 
 
Results 
 
3.1 Establishing RMCE pipeline for V5-snRPB2 
 
We have adapted the RMCE strategy to express a tagged version of a core 
component of the U2 snRNP, snRPB2, in one of the HeLa acceptor lines from 
Khandelia et al. 2011. The EGFP expression marker in pRD-RIPE was replaced 
with V5-tagged snRPB2 via molecular cloning and co-transfected into HeLa with 
a plasmid encoding Cre. HeLa cells that integrated the tagged gene cassette were 
selected for by puromycin selection and tagged gene expression was induced via 
doxycycline induction for 48 hours. Figure 1.4 shows our pipeline for stable 
inducible expression and purification of a tagged core protein of U2 snRNP. 
Stable integration and expression of the gene construct were validated by genomic 
and RT-PCR while tagged protein expression was validated by Western blot. 
Furthermore, Co-IP purification of V5-tagged snRPB2 from active nuclear extract 
of induced HeLa and mass spectrometry of the eluent indicates presence of all 21 
documented proteins of the U2 snRNP suggesting this is a valid pipeline for 
purification and subsequent biochemical studies of human snRNPs.  
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Figure 3.1: Schematic diagram of RMCE pipeline for tagged snRPB2 
expression and subsequent protein purification from HeLa.  
Established acceptor S3-HeLa are co-transfected and selected for by puromycin 
selection. Integration of the donor cassette is validated by PCR of genomic DNA 
with cassette specific primers. Selected cells are grown to confluency and induced 
via addition of doxycycline to the growth media. Tagged V5-snRPB2 expression 
is then validated via RT-PCR of extracted RNA and Western Blot of whole cell or 
nuclear extract of induced HeLa. Following validation, V5-tagged snRPB2 and its 
endogenous interactions are purified via Co-IP which is validated by Western blot 
and mass spectrometry. 
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3.2 Validation of donor cassette integration and 
mRNA expression 
 
 
  
Figure 3.2: PCR and RT-PCR validate donor cassette integration and trans-
gene mRNA expression, respectively. 
(A.) Amplified genomic DNA extracted from transfected HeLa cells alongside a 
1Kb marker in an agarose gel.  
(B.) Agarose gel loaded with amplified cDNA from total RNA extracted from 
induced HeLa cells alongside a 1Kb marker. Each lane loaded with RT-PCR 
product, with the exception of STREP-tagged SF3B3, shows a distinct band in the 
1Kb region. Bands in the tagged EGFP samples depict subtle differences in size 
which correspond to the differences in tags. Of the tagged SF3B3 and snRPB2 
samples, only snRPB2 contains a band running at the expected size of 1Kb. 
(C.) Schematic representation of primer (purple) location relative to the donor 
cassette. 
 
In order to validate genomic integration and expression of our tagged gene 
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upstream and downstream of the trans-gene. Figure 3.2A depicts amplification of 
fragments of expected size for both V5-tagged snRPB2 and V5-tagged EGFP 
samples. Both lanes show a single distinct band in the 1.3Kb region with a subtle 
difference in size. V5 snRPB2 and V5 EGFP both run at the expected sizes of 
~1,300 bp indicating genomic DNA was amplified with region specific primers 
(pRD-ORF Forward and Reverse). In Figure 3.2B, each lane that was loaded with 
RT-PCR product, with the exception of STREP-tagged SF3B3, shows a distinct 
band in the 1Kb region. Bands in the tagged EGFP samples exhibit subtle 
differences in size which correspond to the differences of size between tags. Of 
the tagged SF3B3 and snRPB2 samples, only snRPB2 contains a band running at 
the expected size of 1Kb. 
3.3 Validation of tagged protein expression 
  
Figure 3.3: Presence of V5- tagged protein in whole cell extracts of induced 
HeLa. 
(A.) Immunoblot analysis of whole cell extract from two induced HeLa cell lines 
transfected with V5-tagged snRPB2 and V5-tagged EGFP, respectively. Whole 
cell extracts ran on a 10% SDS-PAGE gel and probed with V5 mouse monoclonal 
antibody (Thermo, cat. #R960-25). Numbers on the side denote protein marker 
sizes in kDa. 
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(B.) Immunoblot analysis of whole cell extract from un-transfected and 
transfected (induced) HeLa cells. Whole cell extracts were run on a 10% SDS-
PAGE gel and probed with α-snRPB2 rabbit polyclonal antibody (Proteintech, 
cat. #13512-1-AP). Numbers on the side denote protein marker sizes in kDa. 
 
Transfected and induced HeLa expressing our tagged gene constructs were 
whole cell extracted in order to assay for expression of V5-tagged protein. Figure 
3.3A and 3.3B depict immunoblots of whole cell extracts from induced HeLa 
cells. In Figure 3.3A, snRPB2 and EGFP extracts were probed for the V5 epitope 
tagged protein, with expected sizes of 27.5 and 28 kDa respectively, and titrated 
alongside a protein ladder. Lanes loaded with snRPB2 extract show detection of 
V5 at 28 kDa with increasing intensity corresponding to the volume loaded in 
each lane. Bands detected in the EGFP lanes exhibit a similar trend to the snRPB2 
lanes, at 28 kDa (Figure 3.3A). Figure 3.3B compares whole cell extracts probed 
for snRPB2 from un-transfected and induced HeLa cells. Three bands detected in 
the un-transfected lane are also seen in the induced lane in the 28-33 kDa region 
with the exception of a fourth band only present in the induced sample indictive 
of the presence of a V5-tagged protein in the transfected sample. 
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3.4 Immuno-purification of tagged protein from HeLa extract 
  
Figure 3.4: Purification of tagged core spliceosome proteins from induced 
HeLa extracts. 
(A.) Western blot of co-immunoprecipitated sample from snRPB2 whole cell 
extract alongside an input sample. Whole cell extract was immunoprecipitated 
with V5 and blots were probed with α-snRPB2 rabbit polyclonal antibody 
(Proteintech, cat. #13512-1-AP). Initial “Elution” was done to prevent Igg 
contamination of the sample. “Mock Elution” is derived from extract + PBS 
(instead of extract + antibody). Hard Elution was done to elute residual proteins 
from the beads in SDS buffer. Unrelated sample was loaded from a separate 
protocol that did not affect the results. Numbers on the side denote protein marker 
sizes in kDa. 
(B.) Western blot of co-immunoprecipitated sample from snRPB2 nuclear extract. 
V5 immunoprecipitated samples were ran alongside a large-scale prepared HeLa 
nuclear extract sample (not a true input but a positive control for the antibody) 
and probed with α-snRPB2 rabbit polyclonal antibody (Proteintech, cat. # 
#13512-1-AP). Initial “Elution” was done to prevent Igg contamination of the 
sample. Mock Elution is derived from extract + PBS (instead of extract + 
antibody). Numbers on the side denote protein marker sizes in kDa. 
(C.) Western blot of co-immunoprecipitated sample from nuclear extract. V5 
immunoprecipitated samples were ran alongside a snRPB2 whole cell extract 
sample (not a true input) and probed with α-SF3B3 rabbit polyclonal antibody 
(Proteintech, cat. #14577-1-AP). Initial “Elution” was done to prevent Igg 
contamination of the sample. Mock Elution is derived from extract + PBS (instead 
of extract + antibody). Numbers on the side denote protein marker sizes in kDa. 
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Once detection of V5-tagged snRPB2 had been established, we wanted to 
determine if other core components of the U2 snRNP would co-
immunoprecipitate with V5-tagged snRPB2. First, we immunoprecipitated 
snRPB2 WCE with V5 antibody and found we can indeed detect purified V5-
tagged snRPB2 from WCE (Figure 3.4A). Given the whole cell extraction 
protocol was done under denaturing conditions (SDS in the RIPA buffer), a mini 
nuclear extract protocol was done under native conditions to preserve endogenous 
interactions with the V5-tagged snRPB2. Using snRPB2 nuclear extract, we were 
able to recapitulate the purification of V5-tagged snRPB2 done in Figure 3.4A 
(Figure 3.4B) as well as detect another core protein, SF3B3, in our snRPB2 
nuclear extract Co-IP sample (Figure 3.4C).  
3.5 Mass spectrometry of immuno-purified sample 
Table 2.3: Mass Spectrometry results of V5-snRPB2 nuclear extract Co-IP 
indicate presence of U2snRNP components. 
 
Rank Gene Num Unique % Cov Protein MW Protein Name
1 SNRPA1 11 42.7 28415.8 U2 small nuclear ribonucleoprotein A'
2 SNRPB2 13 41.3 25486.6 U2 small nuclear ribonucleoprotein B''
3 SNRPF 2 40.7 9725.3 Small nuclear ribonucleoprotein F
4 SF3B2 36 35.1 100228.4 Splicing factor 3B subunit 2
5 PHF5A 4 34.5 12405.6 PHD finger-like domain-containing protein 5A
6 SF3A1 29 33.3 88886.9 Splicing factor 3A subunit 1
7 SNRPE 4 29.3 10803.7 Small nuclear ribonucleoprotein E
8 SF3B6 3 28 14585 Splicing factor 3B subunit 6
9 SF3A3 15 27.5 58849.4 Splicing factor 3A subunit 3
10 SNRPG 3 26.3 8496.2 Small nuclear ribonucleoprotein G
11 SNRPD2 4 24.6 13527 Small nuclear ribonucleoprotein Sm D2
12 SF3B1 24 22.7 145831.6 Splicing factor 3B subunit 1
13 SF3B5 1 19.8 10135.5 Splicing factor 3B subunit 5
14 SNRPD3 6 19 13916.4 Small nuclear ribonucleoprotein Sm D3
15 SF3B3 21 18.6 135578.5 Splicing factor 3B subunit 3
16 SF3A2 10 14.2 49256 Splicing factor 3A subunit 2
17 SNRPD1 1 10.9 13281.7 Small nuclear ribonucleoprotein Sm D1
18 DDX46 8 7.9 117363 Probable ATP-dependent RNA helicase DDX46
19 SF3B4 3 7.8 44386.1 Splicing factor 3B subunit 4
20 SNRPB 4 7.1 24610.3 Small nuclear ribonucleoprotein-associated proteins B and B'
21 HTATSF1 4 5.4 85853.5 HIV Tat-specific factor 1
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Figure 3.5: snRPB2 nuclear extract Co-IP samples was run on a PAGE gel. The 
gel slice containing sample was excised and sent to the UCSF Mass Spectrometry 
facility (Raw data in appendix). The raw data was organized into Table X by the 
components known to comprise the U2snRNP and ranked by % coverage.  
 
Mass spectrometry of the snRPB2 Co-IP sample returned 183 total hits 
(raw data in appendix). Of the 21 U2 snRNP protein components listed in the 
UCSC spliceosome database (reference), all 21 were identified in the snRPB2 Co-
IP sample by mass spectrometry and organized by % coverage (Figure 3.5). 
3.6 Validation of assembly and catalytic activity in 
tagged protein nuclear extract 
 
  
 
Figure 3.6: Assembly and catalytic activity of spliceosome complexes on full 
length substrate with mini-prepped nuclear extracts. 
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(A.) Native agarose gel analysis of complex assembly. 1.9% Native gel loaded 
with splicing reactions spliced for 0, 4, and 15-minutes with nuclear extract from 
HeLa grown in suspension, un-transfected adherent HeLa, and adherent HeLa 
transfected with V5-tagged snRPB2. Letters on the side (B, A, and H/E) denote 
complex identity. Nuclear extract preparation method denoted in parentheses. 
Schematic of pre-mRNA substrate MJ50 (bottom). 
(B.) Denaturing polyacrylamide gel loaded with radio-labeled RNA from in-vitro 
splicing reactions. Pre-mRNA substrate MJ50 was incubated for 15, 30, and 45-
minute time points with nuclear extract from HeLa grown in suspension, un-
transfected adherent HeLa, and adherent HeLa transfected with V5-tagged 
snRPB2. Splicing products and intermediates identities are denoted on the side 
and are as follows (top to bottom): lariat 3’ exon intermediate, lariat, pre-mRNA, 
mRNA, 5’ exon, and linear intron. Nuclear extract preparation method denoted in 
parentheses. Bottom schematic is identical to (A.). 
 
To assay for spliceosome assembly and activity of mini-prepped nuclear 
extracts, radio-labeled full-length pre-mRNA was spliced in-vitro with nuclear 
extracts from un-transfected suspension and adherent HeLa, along with V5 
snRPB2 expressing HeLa. We find that mini-prepped nuclear extracts are indeed 
capable of assembly upon full length pre-mRNA substrates indicated by presence 
of early complexes A and B in un-transfected and B2” V5 lanes compared to that 
of large-scale prepared suspension nuclear extract (Figure 3.6A). Furthermore, 
presence of identical splicing intermediates and products across all lanes in 
Figure 3.6B indicate mini prepped nuclear extracts present comparable catalytic 
activity to large-scale prepared nuclear extract. 
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Chapter 4 
 
Discussion 
 
 4.1 Results Overview 
 
Since the rise of high resolution cryo-EM, structures of fully assembled 
and catalytic spliceosomes in both human and yeast have come to light (reviewed 
by Shi 2019). The structure of stand-alone human spliceosome subunits such as 
the U1 snRNP and the U4/U6.U5 tri-snRNP have also been successfully 
elucidated (Krummel et al. 2009; Agafonov et al. 2016). Currently, a structure-
based mechanism behind branch point selection by the U2 snRNP during 
constitutive and alternative splicing is still an open question in the field.  
In this study, we targeted and tagged a core component of the U2 snRNP 
with the idea that, by preservation of native conditions, purification of the tagged 
core component would result in co-purification of its endogenous interactions thus 
the entire snRNP. In order to establish proof of concept, we adapted an 
established RMCE protocol to express tagged spliceosomal proteins in adherent 
S3-HeLa for purification via in-vitro assays. Remarkably, our results suggest that 
we were able to preserve endogenous interactions between our tagged core 
protein, V5-snRPB2, and all known protein components of the U2 snRNP during 
the nuclear extraction and immuno-purification process prior to elution (Figure 
3.4C and 3.5). These results are also in line with our findings that nuclear extract 
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derived from adherent HeLa expressing tagged V5-snRPB2 is capable of 
assembly and catalytic activity upon exposure to a full-length pre-mRNA 
substrate within in-vitro conditions (Figure 3.6A and 3.6B). Furthermore, we 
were able to validate cassette integration into the HeLa genome (Figure 3.2A) 
and endogenous expression of the trans-gene and tagged protein (Figures 3.2B, 
3.3A, 3.3B) prior to immuno-purification.  
4.2 Protocol Optimization 
Given the strong Ef-1α promoter in front of the cassette, we expected 
overexpression of our tagged construct was likely. This is a possibility we did not 
assay for due to the fact validation of tagged protein expression was sufficient to 
move on to the purification step. Protein overexpression can be consequential to 
the cell by causing stoichiometric imbalances, resource overload, promiscuous 
interactions, and undesired pathway modulations that lead to growth defects 
and/or cell toxicity (Moriya 2015). However, no toxicity or growth defects were 
observed in expression induced HeLa during cell culturing. Despite, no obvious 
evidence of detrimental effects, we could confirm overexpression by qPCR using 
tag specific primers for a quantitative analysis of mRNA expression.  
Another concern we will address is the lack of proper inputs in Figures 
3.4B and 3.4C. Due to the relatively small amounts of extract from the nuclear 
extract mini-preps, we used positive controls for antibodies as opposed to true 
inputs for comparison of starting amounts of protein. Regardless, we are able to 
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observe presence of a single tagged protein associated band in the elution of each 
of our IPs (Figures 3.4B and 3.4C).  
Currently, we are developing a protocol to incorporate a TEV protease 
cleavage site in between the V5 tag and the snRPB2 core protein. We surmise by 
incorporation of this TEV site, elution of snRPB2 and its endogenous interactions, 
without the V5 tag, can be induced by cleavage at the TEV site with TEV 
protease. In order to validate addition of the TEV site has no influence on tagged 
protein expression, we have recapitulated the results shown in Figures 3.3A and 
3.3B (Appendix Figure 1). Furthermore, our data includes additional validation 
of doxycycline induction dependent tagged protein expression. (Appendix Figure 
1).  
4.3 Future Directions 
A core complex of the U2 snRNP, SF3b has been of particular interest due 
to identification of “hot spot mutations” in HEAT domains of the N-terminal 
region in one of its core proteins, SF3B1, that implicate the branch selection 
mechanism with blood cancers (Darman et al. 2015). While the role of these 
mutations in alternate branch selection is unclear, structural data of SF3B1, from 
yeast Bact structure, overlapped with the hotspot mutations found in humans allude 
to a mechanism in which the mutations destabilize a conformation of the pre-
mRNA bound to SF3B1 mutants (Jenkins and Kielkopf, 2017).  
 Pladienolide B (PB), a small molecule compound, among other 
compounds exhibit properties that inhibit or alter splicing. PB in particular binds 
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the SF3b complex and stalls an A-like complex prior to stable A complex 
formation (Yokoi et al. 2011 and Effenberger et al. 2014). Recently, X-ray 
crystallography of a recombinant SF3b complex bound to PB established the PB 
binding site in a crystal structure of the complex bound to drug (Cretu et al. 
2018). Structural data of SF3b bound by PB reveals the binding site of the drug 
and the branch adenosine overlap; moreover, binding of PB locks SFB31 in an 
“open” conformation suggesting in the absence of PB this conformation might be 
“closed” (Cretu et al. 2018). Our lab will utilize the RMCE pipeline to purify U2-
associated components in the presence of small molecule inhibitors in order to 
investigate their binding properties and potentially SF3b-PB structure in the 
context of the full U2 snRNP. 
Future directions of this project will entail developing a pipeline in 
suspension HeLa containing the RMCE acceptor locus for large scale nuclear 
extract preparations, optimization of the co-IP protocol for a TEV protease elution 
and proportional large scale tagged protein purification. Large scale nuclear 
extract preparations, compared to mini-preps, will be necessary considering the 
amount of protein necessary for crystallography or microscopy. A TEV protease 
elution will also be optimal in order to preserve the integrity of endogenous 
interactions as the current protocol calls for denaturing conditions. Given we are 
able to move forward with these optimizations our goals would be to further 
characterize the biochemical profile the U2 snRNP by V5 pull downs. More 
specifically, we hope to uncover more information on the roles of individual 
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snRNP-associated components, their influence on U2 snRNA-protein 
conformation, and their effect on early spliceosome assembly. These studies will 
be done in both native and non-native assembled complexes (in the presence of 
various synthetic substrates). Furthermore, through utility of small molecule 
inhibitors such as PB, V5 pull downs could be used to identify the precise nature 
of the A-like complex accumulated in the presence of PB.  
 In summary, the RMCE pipeline offers a protocol to tag components and 
complexes of the spliceosome purified from HeLa. Our lab was able to utilize 
RMCE to express tagged snRPB2 for co-immuno purification with the remaining 
U2 snRNP proteins. We predict this pipeline will be a useful tool to decipher 
biochemical and structural properties of the U2 snRNP. 
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APPENDIX 
 
 
 
 
  
 
App. Figure 1: Presence of tagged protein in nuclear extracts of induced HeLa  
(A.) Immunoblot analysis of HeLa nuclear extract probed for α-V5. Adherent 
HeLa cells were transfected with plasmid DNA encoding V5 B2” or V5 TEV B2” 
(TEV 1 and TEV 2 denote different plasmid DNA preps) and induced. Un-
transfected and uninduced HeLa were maintained and prepped as a control, as 
well as extract from suspension HeLa for comparison. (B.) Immunoblot probing 
for α-snRPB2 (B2”) loaded with identical samples from (A).  
Addition of TEV site done by Q5 mutagenesis PCR with pRD-RIPE V5-snRPB2.  
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